Insights
Search Results
Client Highlights
9.15.26
Wilson Sonsini Advises DoorDash on $300 Million Acquisition of Wonder’s Grubhub Campus Dining Business
On September 15, 2026, DoorDash, a global leader in local commerce, and Wonder, a leading food technology platform, announced that DoorDash will acquire Wonder's Grubhub Campus Dining business for $300 million. Wilson Sonsini Goodrich & Rosati advised DoorDash on the transaction.
Grubhub Campus Dining, formerly known as Tapingo, enables millions of students at more than 450 colleges and universities to order a meal from campus dining facilities and on-campus restaurants using its mobile app or kiosks, pay for the meal with campus dining dollars, and schedule the pickup. Following the close of the transaction, DoorDash intends to continue expanding Grubhub Campus Dining in the U.S., enhance the selection and convenience available to students, and bring Tapingo’s vertically integrated technology stack beyond college campuses to stadiums, hotels, and other similar venues.
The Wilson Sonsini team that advised DoorDash on the transaction was led by partners Rezwan Pavri, Lang Liu, Sachin Kohli, and Brendan Mahan and associates Ryan Cooper and Jackie Jung. The team also included:
Grubhub Campus Dining, formerly known as Tapingo, enables millions of students at more than 450 colleges and universities to order a meal from campus dining facilities and on-campus restaurants using its mobile app or kiosks, pay for the meal with campus dining dollars, and schedule the pickup. Following the close of the transaction, DoorDash intends to continue expanding Grubhub Campus Dining in the U.S., enhance the selection and convenience available to students, and bring Tapingo’s vertically integrated technology stack beyond college campuses to stadiums, hotels, and other similar venues.
The Wilson Sonsini team that advised DoorDash on the transaction was led by partners Rezwan Pavri, Lang Liu, Sachin Kohli, and Brendan Mahan and associates Ryan Cooper and Jackie Jung. The team also included:
Client Highlights
9.10.26
Wilson Sonsini Advises Blaxel on its Acquisition by Baseten
On September 10, 2026, Baseten, an artificial intelligence inference company, announced that it has acquired Blaxel, an infrastructure company building secure, persistent execution environments for AI agents. The acquisition expands Baseten's platform to bring reliable, secure, and cost-effective infrastructure agents need to run code, use tools, and maintain state. Wilson Sonsini Goodrich & Rosati advised Blaxel on the transaction.
Client Highlights
9.10.26
Wilson Sonsini Advises Copart on Acquisition of ACV
On September 10, 2026, Copart, Inc., a global leader in online vehicle auctions, and ACV, a leading digital automotive marketplace and data services partner for dealers and commercial clients, announced a definitive agreement in which Copart will acquire all outstanding shares of ACV common stock, valued at approximately $1.9 billion. Wilson Sonsini Goodrich & Rosati advised Copart on the transaction.
Client Highlights
9.03.26
Wilson Sonsini Advises Hugging Face on $12.9 Billion Acquisition by NVIDIA
On September 3, 2026, NVIDIA announced that it has agreed to acquire open-source AI platform Hugging Face for $12.9 billion. Together, NVIDIA and Hugging Face plan to scale Hugging Face’s platform, strengthen its infrastructure, and expand access to AI for developers and institutions worldwide. Wilson Sonsini Goodrich & Rosati advised Hugging Face on the transaction.
Client Highlights
8.26.26
Wilson Sonsini Advises Altruist on Acquisition by Vanguard
On August 26, 2026, Vanguard and Altruist, an AI-forward wealth technology and custody platform serving financial advisors, announced that they have entered into a definitive agreement under which Vanguard will acquire Altruist. Wilson Sonsini Goodrich & Rosati is advising Altruist on the transaction.
Client Highlights
8.25.26
Wilson Sonsini Advises Checkr on Acquisition of Truv
On August 18, 2026, Checkr, an AI-powered verification platform for high-stakes decisions, announced the acquisition of Truv, a consumer-permissioned income, employment, and asset verification company. Wilson Sonsini Goodrich & Rosati advised Checkr on the transaction.
Client Highlights
8.20.26
Wilson Sonsini Advises Highspot on Merger with Seismic
On August 18, 2026, Seismic, an AI-powered sales and revenue enablement platform, announced the completion of its merger with Highspot. Following a second request review, the merger obtained U.S. antitrust clearance, which allowed the transaction to close without any action by the Department of Justice Antitrust Division. The combined company will operate under the Seismic name and be led by Seismic Chief Executive Officer Rob Tarkoff. Wilson Sonsini Goodrich & Rosati advised Highspot on the transaction.
Client Highlights
8.03.26
Wilson Sonsini Advises Firefly Bio on $1 Billion Acquisition by Johnson & Johnson
On July 29, 2026, Johnson & Johnson announced the completion of its acquisition of Firefly Bio, a biotechnology company advancing its proprietary Firelink™ degrader antibody conjugate platform, for $1 billion in cash. The Firelink™ DAC platform expands Johnson & Johnson’s oncology portfolio and advances the company’s ambition to develop targeted therapies for some of the most prevalent and difficult-to-treat solid tumors, including KRAS-driven cancers. Wilson Sonsini Goodrich & Rosati advised Firefly Bio on the transaction.
Client Highlights
7.27.26
Firm Advises Forte Biosciences on $2.2 Billion Acquisition by argenx
On July 27, 2026, argenx, a global immunology innovation company, and Forte Biosciences, a clinical-stage biopharmaceutical company, announced that they have entered into a definitive agreement under which argenx will acquire Forte Biosciences for $77.00 per share in cash, representing a total equity value of approximately $2.2 billion. FB102, Forte Biosciences’ lead program, expands argenx’s portfolio of differentiated immunology medicines, adding a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease and potential to address multiple autoimmune diseases. Wilson Sonsini Goodrich & Rosati advised Forte Biosciences on the transaction.
Client Highlights
7.09.26
Wilson Sonsini Advises Beam Benefits on Acquisition by Principal Financial Group
On July 7, 2026, Principal Financial Group announced an agreement to acquire Beam Benefits, an employee benefits company serving more than 25,000 small businesses. Principal currently serves 180,000 employers, providing comprehensive retirement, benefits, and business owner solutions. The acquisition is expected to close in the latter half of 2026, subject to the completion of customary closing conditions and regulatory approvals. Wilson Sonsini Goodrich & Rosati advised Beam Benefits on the transaction.
Client Highlights
6.30.26
Wilson Sonsini Advises Cognite, Major Shareholders on $3.1 Billion Sale to Schneider Electric
On June 30, 2026, Aker ASA (Aker) and the other shareholders of Cognite announced that they have entered into an agreement to sell 100 percent of the shares in Cognite Holding B.V. (Cognite) to Schneider Electric based on an enterprise value of US$3.1 billion. Wilson Sonsini Goodrich & Rosati’s cross-border tech M&A team advised Cognite and its major shareholders, including Aker, TCV, and Accel, on the transaction.
Client Highlights
6.24.26
Wilson Sonsini Advises Saturnus Bio on Strategic Collaboration with Merck KGaA, Darmstadt, Germany
On June 23, 2026, Merck KGaA, Darmstadt, Germany, a leading global science and technology company, announced a strategic collaboration with Versant Ventures to launch Saturnus Bio, a next-generation precision cardiology company that utilizes targeted gene modulation to address rare mono-genetic cardiomyopathies with significant unmet need. Wilson Sonsini Goodrich & Rosati advised Saturnus Bio on the transaction.
The research-stage partnership entails a build-to-buy deal structure, including an upfront payment of $50 million from Merck KGaA, Darmstadt, Germany to fund Saturnus Bio’s research activities, securing a minority equity stake in the company, as well as additional success-based preclinical milestones, supporting the development of novel drug candidates for genetic cardiomyopathy patients. Merck KGaA, Darmstadt, Germany has exclusive rights to acquire Saturnus Bio for a pre-determined option payment, in addition to success-based earnouts.
The Wilson Sonsini team that advised Saturnus Bio on the transaction includes:
The research-stage partnership entails a build-to-buy deal structure, including an upfront payment of $50 million from Merck KGaA, Darmstadt, Germany to fund Saturnus Bio’s research activities, securing a minority equity stake in the company, as well as additional success-based preclinical milestones, supporting the development of novel drug candidates for genetic cardiomyopathy patients. Merck KGaA, Darmstadt, Germany has exclusive rights to acquire Saturnus Bio for a pre-determined option payment, in addition to success-based earnouts.
The Wilson Sonsini team that advised Saturnus Bio on the transaction includes: